The evolution of systemic therapy in sarcoma

Expert Review of Anticancer Therapy

Volumn 13, Issue 2, 2013, Pages 211-223

  Constantinidou, Anastasia ^a   Pollack, Seth ^b   Loggers, Elizabeth ^b   Rodler, Eve ^b   Jones, Robin L ^b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

angiogenesis; gemcitabine docetaxel; pazopanib; rare histological subtype; sarcoma; systemic therapy; trabectedin

Indexed keywords

BEVACIZUMAB; BRIVANIB; CEDIRANIB; CISPLATIN; COLONY STIMULATING FACTOR 1; CRIZOTINIB; DENOSUMAB; DOCETAXEL; DOXORUBICIN; ETHANOLAMINE DERIVATIVE; FIGITUMUMAB; GEMCITABINE; IFOSFAMIDE; IMATINIB; METHOTREXATE; MURAMYL TRIPEPTIDE; MURAMYL TRIPEPTIDE PHOSPHATIDYL ETHANOLAMINE; NILOTINIB; OSTEOCLAST DIFFERENTIATION FACTOR; PACLITAXEL; PAMIDRONIC ACID; PAZOPANIB; PLACEBO; PLATELET DERIVED GROWTH FACTOR B; RAPAMYCIN; RIDAFOROLIMUS; SORAFENIB; SUNITINIB; TRABECTEDIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADVANCED CANCER; ALVEOLAR SOFT PART SARCOMA; ANEMIA; ANGIOSARCOMA; ANOREXIA; ARTHRALGIA; BONE MARROW SUPPRESSION; CANCER LOCALIZATION; CANCER RESISTANCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHORDOMA; CLINICAL EFFECTIVENESS; COLLAGEN 6A3 GENE; COLLAGEN TYPE I A1 GENE; DERMATOFIBROSARCOMA PROTUBERANS; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EWING SARCOMA; FATIGUE; FLUID RETENTION; GASTROINTESTINAL STROMAL TUMOR; HAND FOOT SYNDROME; HEART DISEASE; HEMANGIOENDOTHELIOMA; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPOCALCEMIA; HYPOPHOSPHATEMIA; INTERSTITIAL LUNG DISEASE; INTESTINE PERFORATION; JAW OSTEONECROSIS; LEUKOPENIA; LIPOSARCOMA; LIVER FUNCTION; LUNG EMBOLISM; LUNG TOXICITY; M CSF GENE; METASTASIS; MOLECULAR PATHOLOGY; MULTIPLE CYCLE TREATMENT; MYALGIA; MYOSARCOMA; NEPHROTOXICITY; NEUTROPENIA; ONCOGENE; OSTEOCLASTOMA; OSTEOSARCOMA; OTOTOXICITY; PANCREATITIS; PDGFB GENE; PERIPHERAL EDEMA; PIGMENTED VILLONODULAR SYNOVITIS; PLASMA CELL GRANULOMA; PNEUMONIA; PNEUMOTHORAX; PROGRESSION FREE SURVIVAL; RESPIRATORY DISTRESS; REVIEW; SARCOMA; SIDE EFFECT; SKIN TOXICITY; SOFT TISSUE SARCOMA; SOLID TUMOR; SYNOVIAL SARCOMA; SYSTEMIC THERAPY; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; UTERUS SARCOMA; VENOUS THROMBOEMBOLISM; WEIGHT REDUCTION;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHORDOMA; DEOXYCYTIDINE; DERMATOFIBROSARCOMA; DIOXOLES; DRUG RESISTANCE, NEOPLASM; HEMANGIOSARCOMA; HUMANS; OSTEOSARCOMA; PROTEASOME INHIBITORS; RECEPTOR, IGF TYPE 1; SARCOMA; SOFT TISSUE NEOPLASMS; TAXOIDS; TETRAHYDROISOQUINOLINES; TOR SERINE-THREONINE KINASES;

EID: 84873926745     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.161     Document Type: Review

References (111)

1. Fletcher CDM, Unni KK, Mertens F. Pathology and genetics: tumours of soft tissue and bone. WHO, Geneva, Switzerland (2002).
2. Clark MA, Fisher C, Judson I, Thomas JM. Soft-tissue sarcomas in adults. N. Engl. J. Med. 353(7), 701-711 (2005).
3. Krikelis D, Judson I. Role of chemotherapy in the management of soft tissue sarcomas. Expert Rev. Anticancer Ther. 10 (2), 249-260 (2010).
4. Wunder JS, Nielsen TO, Maki RG, O'Sullivan B, Alman BA. Opportunities for improving the therapeutic ratio for patients with sarcoma. Lancet Oncol. 8(6), 513-524 (2007).
5. Penel N, Bui BN, Bay JO et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J. Clin. Oncol. 26(32), 5269-5274 (2008).
6. Fury MG, Antonescu CR, Van Zee KJ, Brennan MF, Maki RG. A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J. 11(3), 241-247 (2005).
7. Eiling S, Lischner S, Busch JO, Rothaupt D, Christophers E, Hauschild A. Complete remission of a radio-resistant cutaneous angiosarcoma of the scalp by systemic treatment with liposomal doxorubicin. Br. J. Dermatol. 147(1), 150-153 (2002).
8. Hensley ML, Maki R, Venkatraman E et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a Phase II trial. J. Clin. Oncol. 20(12), 2824-2831 (2002).
9. Constantinidou A, Jones RL, Scurr M, Al-Muderis O, Judson I. Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fbromatosis. Eur. J. Cancer 45(17), 2930-2934 (2009).
10. Jones RL, Constantinidou A, Thway K et al. Chemotherapy in clear cell sarcoma. Med. Oncol. 28(3), 859-863 (2011).
11. Reichardt P, Lindner T, Pink D, Thuss-Patience PC, Kretzschmar A, Dörken B. Chemotherapy in alveolar soft part sarcomas. What do we know? Eur. J. Cancer 39(11), 1511-1516 (2003).
12. Jones RL, Fisher C, Al-Muderis O, Judson IR. Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur. J. Cancer 41(18), 2853-2860 (2005).
13. Constantinidou A, Jones RL, Olmos D et al. Conventional anthracycline-based chemotherapy has limited effcacy in solitary fbrous tumour. Acta Oncol. 51(4), 550-554 (2012).
14. Jones RL, Olmos D, Thway K et al. Clinical beneft of early phase clinical trial participation for advanced sarcoma patients. Cancer Chemother. Pharmacol. 68(2), 423-429 (2011).
15. Jones RL, McCall J, Adam A et al. Radiofrequency ablation is a feasible therapeutic option in the multi modality management of sarcoma. Eur. J. Surg. Oncol. 36(5), 477-482 (2010).
16. Karavasilis V, Seddon BM, Ashley S, Al-Muderis O, Fisher C, Judson I. Signifcant clinical beneft of frst-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identifcation of prognostic factors in 488 patients. Cancer 112(7), 1585-1591 (2008).
17. Shimizu A, O'Brien KP, Sjöblom T et al. The dermatofbrosarcoma protuberans-associated collagen type I Ct1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res. 59(15), 3719-3723 (1999).
18. Sjöblom T, Shimizu A, O'Brien KP et al. Growth inhibition of dermatofbrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res. 61(15), 5778-5783 (2001).
19. Maki RG, Awan RA, Dixon RH, Jhanwar S, Antonescu CR. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofbrosarcoma protuberans. Int. J. Cancer 100(6), 623-626 (2002).
20. Rubin BP, Schuetze SM, Eary JF et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofbrosarcoma protuberans. J. Clin. Oncol. 20(17), 3586-3591 (2002)
21. Labropoulos SV, Fletcher JA, Oliveira AM, Papadopoulos S, Razis ED. Sustained complete remission of metastatic dermatof-brosarcoma protuberans with imatinib mesylate. Anticancer. Drugs 16(4), 461-466 (2005).
22. McArthur GA, Demetri GD, van Oosterom A et al. Molecular and clinical analysis of locally advanced dermatofbrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J. Clin. Oncol. 23(4), 866-873 (2005).
23. Rutkowski P, Van Glabbeke M, Rankin CJ et al.; European Organisation for Research and Treatment of Cancer Soft Tissue/Bone Sarcoma Group; Southwest Oncology Group. Imatinib mesylate in advanced dermatofbrosarcoma protuberans: pooled analysis of two Phase II clinical trials. J. Clin. Oncol. 28(10), 1772-1779 (2010).
24. Casali PG, Stacchiotti S, Sangalli C, Olmi P, Gronchi A. Chordoma. Curr. Opin. Oncol. 19(4), 367-370 (2007).
25. Casali PG, Messina A, Stacchiotti S et al. Imatinib mesylate in chordoma. Cancer 101(9), 2086-2097 (2004).
26. Stacchiotti S, Longhi A, Ferraresi V et al. Phase II study of imatinib in advanced chordoma. J. Clin. Oncol. 30(9), 914-920 (2012).
27. Stacchiotti S, Marrari A, Tamborini E et al. Response to imatinib plus sirolimus in advanced chordoma. Ann. Oncol. 20(11), 1886-1894 (2009).
28. Shalaby A, Presneau N, Ye H et al. The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target. J. Pathol. 223(3), 336-346 (2011).
29. West RB, Rubin BP, Miller MA et al. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc. Natl Acad. Sci. USA 103(3), 690-695 (2006).
30. Cupp JS, Miller MA, Montgomery KD et al. Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides. Am. J. Surg. Pathol. 31(6), 970-976 (2007).
31. Blay JY, El Sayadi H, Thiesse P, Garret J, Ray-Coquard I. Complete response to imatinib in relapsing pigmented villonodu-lar synovitis/tenosynovial giant cell tumor (PVNS/TGCT). Ann. Oncol. 19(4), 821-822 (2008).
32. Cassier PA, Gelderblom H, Stacchiotti S et al. Effcacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. Cancer 118(6), 1649-1655 (2012).
33. Szendröi M. Giant-cell tumour of bone. J. Bone Joint Surg. Br. 86(1), 5-12 (2004).
34. Roudier MP, Keller-Graney KL, Huang LY et al. RANK and RANKL expression in giant cell tumors of the bone: an immunohistochemical study. Presented at: Connective Tissue Oncology Society Annual Meeting. Venice, Italy, 2-4 November 2006.
35. Roudier MP, Keller-Graney KL, Huang LY et al. Increased RANKL in giant cell tumors of the bone correlates with recurrence. Presented at: 13th Annual Connective Tissue Oncology Society Meeting. Seattle, WA, USA, 1-3 November 2007.
36. Thomas D, Henshaw R, Skubitz K et al. Denosumab in patients with giant-cell tumour of bone: an open-label, Phase 2 study. Lancet Oncol. 11(3), 275-280 (2010).
37. Butrynski JE, D'Adamo DR, Hornick JL et al. Crizotinib in ALK-r ear ranged infammatory myofbroblastic tumor. N. Engl. J. Med. 363(18), 1727-1733 (2010).
38. Fidler IJ, Sone S, Fogler WE, Barnes ZL. Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide. Proc. Natl Acad. Sci. USA 78(3), 1680-1684 (1981).
39. MacEwen EG, Kurzman ID, Rosenthal RC et al. Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide. J. Natl Cancer Inst. 81(12), 935-938 (1989).
40. Kleinerman ES, Snyder JS, Jaffe N. Infuence of chemotherapy administration on monocyte activation by liposomal muramyl tripeptide phosphatidylethanol-amine in children with osteosarcoma. J. Clin. Oncol. 9(2), 259-267 (1991).
41. Kleinerman ES, Meyers PA, Raymond AK, Gano JB, Jia SF, Jaffe N. Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulation. J. Immunother. Emphasis Tumor Immunol. 17(3), 181-193 (1995).
42. Meyers PA, Schwartz CL, Krailo MD et al.; Children's Oncology Group. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival-a report from the Children's Oncology Group. J. Clin. Oncol. 26(4), 633-638 (2008).
43. Meyers PA, Schwartz CL, Krailo M et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J. Clin. Oncol. 23(9), 2004-2011 (2005).
44. Meyers PA, Healey JH, Chou AJ et al. Addition of pamidronate to chemotherapy for the treatment of osteosarcoma. Cancer 117(8), 1736-1744 (2011).
45. Italiano A, Cioff A, Penel N et al. Comparison of doxorubicin and weekly paclitaxel effcacy in metastatic angiosarcomas. Cancer 118(13), 3330-3336 (2012).
46. Agulnik M, Yarber JL, Okuno SH et al. An open-label, multicenter, Phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann. Oncol. 24(1), 257-263 (2013).
47. Verschraegen CF, Arias-Pulido H, Lee SJ et al. Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen. Ann. Oncol. 23(3), 785-790 (2012).
48. Ray-Coquard I, Italiano A, Bompas E et al.; French Sarcoma Group (GSF/GETO). Sorafenib for patients with advanced angiosarcoma: a Phase II Trial from the French Sarcoma Group (GSF/GETO). Oncologist 17(2), 260-266 (2012).
49. Gardner K, Judson I, Leahy M et al Activity of cediranib, a highly potent VEGF signaling inhibitor, in alveolar soft part sarcoma. J. Clin. Oncol. 27, Abstract 10523 (2009).
50. Stacchiotti S, Tamborini E, Marrari A et al Response to sunitinib malate in advanced alveolar soft part sarcoma. Clin. Cancer Res. 15(3), 1096-1104 (2009).
51. Kummar S, Strassberger A, Monks A, et al An evaluation of cediranib as a new agent for alveolar soft part sarcoma (ASPS). J. Clin. Oncol. 29, Abstract 10001 (2011).
52. Hensley ML, Blessing JA, Degeest K, Abulafa O, Rose PG, Homesley HD. Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group Phase II study. Gynecol Oncol. 109(3), 323-328 (2008).
53. Hensley ML, Blessing JA, Mannel R, Rose PG. Fixed-dose rate gemcitabine plus docetaxel as frst-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group Phase II trial. Gynecol Oncol. 109(3), 329-334 (2008).
54. Maki RG, Wathen JK, Patel SR et al. Randomized Phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J. Clin. Oncol. 25(19), 2755-2763 (2007).
55. Pautier P, Floquet A, Penel N et al Randomized multicenter and stratifed Phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study). Oncologist 17(9), 1213-1220 (2012).
56. Schöffski P, Taron M, Jimeno J et al Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study. Eur. J. Cancer 47(7), 1006-1012 (2011).
57. Grosso F, Jones RL, Demetri GD et al Effcacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarco-mas: a retrospective study. Lancet Oncol. 8(7), 595-602 (2007).
58. Yovine A, Riofrio M, Blay JY et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J. Clin. Oncol. 22(5), 890-899 (2004).
59. Le Cesne A, Blay JY, Judson I et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J. Clin. Oncol. 23(3), 576-584 (2005).
60. Garcia-Carbonero R, Supko JG, Manola J et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J. Clin. Oncol 22(8), 1480-1490 (2004).
61. Demetri GD, Chawla SP, von Mehren M et al. Effcacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized Phase II study of two different schedules. J. Clin. Oncol. 27(25), 4188-4196 (2009).
62. Gronchi A, Bui BN, Bonvalot S et al. Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. Ann. Oncol. 23(3), 771-776 (2011).
63. Sanflippo R, Grosso F, Jones RL et al. Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers. Gynecol. Oncol 123(3), 553-556 (2011).
64. Monk BJ, Blessing JA, Street DG, Muller CY, Burke JJ, Hensley ML. A Phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study. Gynecol. Oncol. 124(1), 48-52 (2012).
65. Laverdiere C, Kolb EA, Supko JG et al. Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. Cancer 98(4), 832-840 (2003).
66. Le Cesne A, Yovine A, Blay JY et al. A retrospective pooled analysis of trabectedin safety in 1, 132 patients with solid tumors treated in Phase II clinical trials. Invest. New Drugs 30(3), 1193-1202 (2012).
67. Pakos EE, Goussia AC, Tsekeris PG, Papachristou DJ, Stefanou D, Agnantis NJ. Expression of vascular endothelial growth factor and its receptor, KDR/Flk-1, in soft tissue sarcomas. Anticancer Res. 25(5), 3591-3596 (2005).
68. Chao C, Al-Saleem T, Brooks JJ, Rogatko A, Kraybill WG, Eisenberg B. Vascular endothelial growth factor and soft tissue sarcomas: tumor expression correlates with grade. Ann. Surg. Oncol. 8(3), 260-267 (2001).
69. Yudoh K, Kanamori M, Ohmori K, Yasuda T, Aoki M, Kimura T. Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas. Br. J. Cancer 84(12), 1610-1615 (2001).
70. Graeven U, Andre N, Achilles E, Zornig C, Schmiegel W. Serum levels of vascular endothelial growth factor and basic fbroblast growth factor in patients with soft-tissue sarcoma. J. Cancer Res. Clin. Oncol. 125(10), 577-581 (1999).
71. Hayes AJ, Mostyn-Jones A, Koban MU, A'Hern R, Burton P, Thomas JM. Serum vascular endothelial growth factor as a tumour marker in soft tissue sarcoma. Br. J. Surg. 91(2), 242-247 (2004).
72. Feldman AL, Pak H, Yang JC, Alexander HR Jr, Libutti SK. Serum endostatin levels are elevated in patients with soft tissue sarcoma. Cancer 91 (8), 1525-1529 (2001).
73. Kuhnen C, Lehnhardt M, Tolnay E, Muehlberger T, Vogt PM, Müller KM. Patterns of expression and secretion of vascular endothelial growth factor in malignant soft-tissue tumours. J. Cancer Res. Clin. Oncol. 126(4), 219-225 (2000).
74. von Mehren M, Rankin C, Goldblum JR et al. Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas. Cancer 118(3), 770-776 (2012).
75. Maki RG, DAdamo DR, Keohan ML et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J. Clin. Oncol. 27(19), 3133-3140 (2009).
76. George S, Merriam P, Maki RG et al. Multicenter Phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J. Clin. Oncol. 27(19), 3154-3160 (2009).
77. Choi H, Charnsangavej C, Faria SC et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J. Clin. Oncol. 25(13), 1753-1759 (2007).
78. Van Glabbeke M, Verweij J, Judson I, Nielsen OS; EORTC Soft Tissue and Bone Sarcoma Group. Progression-free rate as the principal end-point for Phase II trials in soft-tissue sarcomas. Eur. J. Cancer 38(4), 543-549 (2002).
79. Sleijfer S, Ray-Coquard I, Papai Z et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a Phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J. Clin. Oncol. 27(19), 3126-3132 (2009).
80. van der Graaf WT, Blay JY, Chawla SP et al.; EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled Phase 3 trial. Lancet 379(9829), 1879-1886 (2012).
81. Schwartz GK, Maki RG, Ratain MJ et al. Brivanib (BMS-582664) in advanced soft-tissue sarcoma (STS): biomarker and subset results of a Phase II randomized discontinuation trial. J. Clin. Oncol. 29, Abstract 10000 (2011).
82. Olmos D, Tan DS, Jones RL, Judson IR. Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside. Cancer J. 16(3), 183-194 (2010).
83. Olmos D, Postel-Vinay S, Molife LR et al. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody fgitumumab (CP-751, 871) in patients with sarcoma and Ewing's sarcoma: a Phase 1 expansion cohort study. Lancet Oncol. 11(2), 129-135 (2010).
84. Pappo AS, Patel SR, Crowley J et al. R 1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a Phase II Sarcoma Alliance for Research through Collaboration study. J. Clin. Oncol. 29(34), 4541-4547 (2011).
85. Juergens H, Daw NC, Geoerger B et al. Preliminary effcacy of the anti-insulin-like growth factor type 1 receptor antibody fgitumumab in patients with refractory Ewing sarcoma. J. Clin. Oncol. 29(34), 4534-4540 (2011).
86. Wan X, Helman LJ. The biology behind mTOR inhibition in sarcoma. Oncologist 12 (8), 1007-1018 (2007).
87. Chawla SP, Staddon AP, Baker LH et al. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J. Clin. Oncol. 30(1), 78-84 (2012).
88. Mita MM, Britten CD, Poplin E et al. Deforolimus trial 106-A Phase I trial evaluating 7 regimens of oral Deforolimus (AP23573, MK-8669). J. Clin. Oncol. 26, Abstract 3509 (2008).
89. Chawla SP, Blay J, Ray-Coquard IL et al. Results of the Phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical beneft from prior standard cytotoxic chemotherapy (CT). J. Clin. Oncol. 29, Abstract 10005 (2011).
90. Okuno S, Bailey H, Mahoney MR et al. A Phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: a study of the Mayo Phase 2 consortium (P2C). Cancer 117 (15), 3468-3475 (2011).
91. Wagner AJ, Malinowska-Kolodziej I, Morgan JA et al. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J. Clin. Oncol. 28(5), 835-840 (2010).
92. Wagner AJ, Von Hoff DH, Lorusso PM. A frst-in-human Phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors. J. Clin. Oncol. 27, 15s (2009).
93. Maki RG, Kraft AS, Scheu K et al. A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas. Cancer 103(7), 1431-1438 (2005).
94. Lu G, Punj V, Chaudhary PM. Proteasome inhibitor Bortezomib induces cell cycle arrest and apoptosis in cell lines derived from Ewing's sarcoma family of tumors and synergizes with TRAIL. Cancer Biol. Ther. 7(4), 603-608 (2008).
95. Nakamura T, Tanaka K, Matsunobu T et al. The mechanism of cross-resistance to proteasome inhibitor bortezomib and overcoming resistance in Ewing's family tumor cells. Int. J. Oncol. 31(4), 803-811 (2007).
96. Shapovalov Y, Benavidez D, Zuch D, Eliseev RA. Proteasome inhibition with bortezomib suppresses growth and induces apoptosis in osteosarcoma. Int. J. Cancer 127(1), 67-76 (2010).
97. Bersani F, Taulli R, Accornero P et al. Bortezomib-mediated proteasome inhibition as a potential strategy for the treatment of rhabdomyosarcoma. Eur. J. Cancer 44(6), 876-884 (2008).
98. Towle MJ, Salvato KA, Budrow J et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res. 61(3), 1013-1021 (2001).
99. Jordan MA, Kamath K, Manna T et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol. Cancer Ther. 4(7), 1086-1095 (2005).
100. Okouneva T, Azarenko O, Wilson L, Littlefeld BA, Jordan MA. Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol. Cancer Ther. 7(7), 2003-2011 (2008).
101. Schöffski P, Ray-Coquard IL, Cioff A et al.; European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG). Activity of eribulin mesylate in patients with soft-tissue sarcoma: a Phase 2 study in four independent histological subtypes. Lancet Oncol. 12(11), 1045-1052 (2011).
102. Verschraegen CF, Chawla SP, Mita MM et al.; Picasso Study Investigators. A Phase II, randomized, controlled trial of palifosfamide plus doxorubicin versus doxorubicin in patients with soft tissue sarcoma (PICASSO). J. Clin. Oncol. 28(15s Suppl.), Abstract 10004 (2010).
103. Rajendran JG, Hendrickson KR, Spence AM, Muzi M, Krohn KA, Mankoff DA. Hypoxia imaging-directed radiation treatment planning. Eur. J. Nucl. Med. Mol. Imaging 33(Suppl. 1), 44-53 (2006).
104. Brizel DM, Scully SP, Harrelson JM et al. Radiation therapy and hyperthermia improve the oxygenation of human soft tissue sarcomas. Cancer Res. 56(23), 5347-5350 (1996).
105. Jung D, Lin L, Jiao H, Cai X, Duan JX, Matteucci M. Pharmacokinetics of TH-302: a hypoxically activated prodrug of bromo-isophosphoramide mustard in mice, rats, dogs and monkeys. Cancer Chemother. Pharmacol. 69(3), 643-654 (2011).
106. Weiss GJ, Infante JR, Chiorean EG et al. Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies. Clin. Cancer Res. 17(9), 2997-3004 (2011).
107. Ganjoo KN, Cranmer LD, Butrynski JE et al. A Phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. Oncology 80(1-2), 50-56 (2011).
108. Pollack SM, Loggers ET, Rodler ET, Yee C, Jones RL. Immune-based therapies for sarcoma. Sarcoma 2011, 438940 (2011).
109. Jungbluth AA, Busam KJ, Kolb D et al. Expression of MAGE-antigens in normal tissues and cancer. Int. J. Cancer 85(4), 460-465 (2000).
110. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat. Rev. Cancer 5(8), 615-625 (2005).
111. Robbins PF, Morgan RA, Feldman SA et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29(7), 917-924 (2011).